Bria Giddens
Family · Dallas, TXNPI 1609540186
Payments from drug & device makers
Across 121 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$408
- AbbVie$290
- Novo Nordisk$289
- GSK$278
- Lilly USA, LLC$263
- Astellas Pharma US Inc$261
- plus $909 from 22 others
What the payments were for
- Food & beverage$2,698100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $408 |
| AbbVie | 15 | $290 |
| Novo Nordisk | 12 | $289 |
| GSK | 15 | $278 |
| Lilly USA, LLC | 17 | $263 |
| Astellas Pharma US Inc | 10 | $261 |
| Vanda Pharmaceuticals Inc. | 4 | $144 |
| Dexcom, Inc. | 8 | $134 |
| Pfizer | 4 | $94 |
| Exact Sciences | 4 | $68 |
| Amarin Pharma, Inc. | 3 | $68 |
| Boehringer Ingelheim | 3 | $59 |
| Abbott | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Eisai Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Echosens North America, Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Gilead | 1 | $20 |
| Renalytix AI, Inc. | 1 | $19 |
| Inogen, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| BD | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $12 |
| Angiodynamics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,698 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $11,371 |
| JardianceEmpagliflozin | 14 | $9,455 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,745 |
| Nebivolol Hcl | 14 | $759 |
| Atorvastatin Calcium | 48 | $526 |
| Olmesartan Medoxomil | 16 | $455 |
| Gabapentin | 51 | $438 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $355 |
| Metformin Hcl ErMetformin Hcl | 19 | $334 |
| Amlodipine Besylate | 51 | $322 |
| Duloxetine Hcl | 15 | $320 |
| Fluticasone Propionate | 34 | $319 |
| Quetiapine Fumarate | 13 | $297 |
| Tizanidine Hcl | 27 | $288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $263 | $11,37111 claims |
| Boehringer IngelheimJardiance | $59 | $9,45514 claims |
| GSKTrelegy Ellipta | $278 | $8,74511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Hayley McKessonDallas$165K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Richard OrnbergDallas$56K
- Ifeoma OkekeDallas$48K
- Natasha SimmonsDallas$38K
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.